SEARCH

SEARCH BY CITATION

References

  • Aman M, Hirano M, Kanaide H, Hirano K (2010). Upregulation of proteinase-activated receptor-2 and increased response to trypsin in endothelial cells after exposure to oxidative stress in rat aortas. J Vasc Res 47: 494506.
  • Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K (2008). Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 16291637.
  • Cao J, Kitazawa T, Takehana K, Taneike T (2006). Endogenous prostaglandins regulate spontaneous contractile activity of uterine strips isolated from non-pregnant pigs. Prostaglandins Other Lipid Mediat 81: 93105.
  • Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P et al. (1999). Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation 99: 25902597.
  • Cosentino F, Luscher TF (1998). Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32 (Suppl. 3): S54S61.
  • Damiano BP, D'Andrea MR, de Garavilla L, Cheung WM, Andrade-Gordon P (1999). Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb Haemost 81: 808814.
  • Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005). Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111: 14481454.
  • Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E et al. (2005). COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 67: 723735.
  • Hamilton JR, Frauman AG, Cocks TM (2001). Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res 89: 9298.
  • Hansen KK, Oikonomopoulou K, Li Y, Hollenberg MD (2008). Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems. Naunyn Schmiedebergs Arch Pharmacol 377: 377392.
  • Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ (1998). Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 14: 241249.
  • Ikeoka D, Pachler C, Korsatko S, Mader JK, Weinhandl H, Bodenlenz M et al. (2010). Interleukin-6 produced in subcutaneous adipose tissue is linked to blood pressure control in septic patients. Cytokine 50: 284291.
  • Kagota S, Yamaguchi Y, Tanaka N, Kubota Y, Kobayashi K, Nejime N et al. (2006). Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci 78: 11871196.
  • Kagota S, Fukushima K, Umetani K, Tada Y, Nejime N, Nakamura K et al. (2010). Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome. Clin Exp Pharmacol Physiol 37: 10351043.
  • Kennedy AJ, Ellacott KL, King VL, Hasty AH (2010). Mouse models of the metabolic syndrome. Dis Model Mech 3: 156166.
  • Levy J, Gavin JR, III, Sowers JR (1994). Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 96: 260273.
  • McGuire JJ, Dai J, Andrade-Gordon P, Triggle CR, Hollenberg MD (2002a). Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther 303: 985992.
  • McGuire JJ, Hollenberg MD, Andrade-Gordon P, Triggle CR (2002b). Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol 135: 155169.
  • McGuire JJ, Hollenberg MD, Bennett BM, Triggle CR (2004). Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. Can J Physiol Pharmacol 82: 11031112.
  • McGuire JJ, Van Vliet BN, Gimenez J, King JC, Halfyard SJ (2007). Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice. Pflugers Arch 454: 535543.
  • Matsumoto T, Ishida K, Taguchi K, Kobayashi T, Kamata K (2009). Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery. Peptides 30: 17291734.
  • Miike T, Kunishiro K, Kanda M, Azukizawa S, Kurahashi K, Shirahase H (2008). Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice–possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn Schmiedebergs Arch Pharmacol 377: 401410.
  • Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A et al. (1997). Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272: 40434049.
  • Nacci C, Tarquinio M, De BL, Mauro A, Zigrino A, Carratu MR et al. (2009). Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. Endocrinology 150: 849861.
  • Napoli C, de Nigris F, Wallace JL, Hollenberg MD, Tajana G, De Rosa G et al. (2004). Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions. J Clin Pathol 57: 513516.
  • Okon EB, Szado T, Laher I, McManus B, van Breemen C (2003). Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 40: 520530.
  • Pannirselvam M, Verma S, Anderson TJ, Triggle CR (2002). Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 136: 255263.
  • Pannirselvam M, Ding H, Anderson TJ, Triggle CR (2006). Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. Eur J Pharmacol 551: 98107.
  • Paoletti R, Bolego C, Poli A, Cignarella A (2006). Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag 2: 145152.
  • Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C (2008). Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 295: H1982H1988.
  • Pfaffl MW, Horgan GW, Dempfle L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
  • Ramachandran R, Hollenberg MD (2008). Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153 (Suppl. 1): S263S282.
  • Roviezzo F, Bucci M, Brancaleone V, Di LA, Geppetti P, Farneti S et al. (2005). Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol 25: 23492354.
  • Russell JC, Proctor SD (2006). Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 15: 318330.
  • Shaw DI, Hall WL, Williams CM (2005). Metabolic syndrome: what is it and what are the implications? Proc Nutr Soc 64: 349357.
  • Smeda JS, McGuire JJ (2007). Effects of poststroke Losartan versus Captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. Stroke 38: 15901596.
  • Smeda JS, McGuire JJ, Daneshtalab N (2010). Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats. Peptides 31: 227237.
  • Sobey CG, Cocks TM (1998). Activation of protease-activated receptor-2 (PAR-2) elicits nitric oxide-dependent dilatation of the basilar artery in vivo. Stroke 29: 14391444.
  • Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A et al. (2006). Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 99: e12e17.
  • Venkatapuram S, Shannon RP (2006). Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome. Am J Ther 13: 6471.
  • Yamada Y, Yamauchi D, Yokoo M, Ohinata K, Usui H, Yoshikawa M (2008). A potent hypotensive peptide, novokinin, induces relaxation by AT2- and IP-receptor-dependent mechanism in the mesenteric artery from SHRs. Biosci Biotechnol Biochem 72: 257259.
  • Zhang H, Zhang C (2009). Regulation of microvascular function by adipose tissue in obesity and type 2 diabetes: evidence of an adipose-vascular loop. Am J Biomed Sci 1: 133142.